

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Neurology</b>				
Neurology	Serotonin (5-HT <sub>6</sub> ) receptor (HTR6)	<p>SAR studies identified a series of indenylsulfonamides that could treat neuropsychological disorders. Using scaffold selection, an indole to indene core change led to a series of indenylsulfonamides that potently and selectively agonized HTR6. Additional chemical modifications increased the compounds' potency, with one compound showing <math>K_i</math> and <math>EC_{50}</math> values in the low nanomolar range. Next steps could include testing the new series of compounds <i>in vivo</i>. At least seven companies have HTR6 antagonists in clinical and preclinical testing to treat obesity or neurological conditions.</p> <p><b>SciBX 2(9); doi:10.1038/scibx.2009.375</b> <b>Published online March 5, 2009</b></p>	Patent and licensing status unavailable	<p>Alcalde, E. <i>et al. J. Med. Chem.</i>; published online Jan. 21, 2009; doi:10.1021/jm8009469</p> <p><b>Contact:</b> Ermitas Alcalde, University of Barcelona, Barcelona, Spain e-mail: <a href="mailto:ecalcalde@ub.edu">ecalcalde@ub.edu</a></p>